Literature DB >> 421218

N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat.

R C Moon, H J Thompson, P J Becci, C J Grubbs, R J Gander, D L Newton, J M Smith, S L Phillips, W R Henderson, L T Mullen, C C Brown, M B Sporn.   

Abstract

The synethesis of a new retinoid, N-(4-hydroxyphenyl)-all-trans-retinamide, which has useful biological properties, is described. This retinoid was more potent than retinyl acetate in reversing keratinization caused by retinoid deficiency in tracheal organ culture. It was markedly less toxic than retinyl acetate when fed p.o. to rats over 2-week or 6-month periods. It was an effective agent for inhibition of the development of breast cancer induced in rats by N-nitroso-N-methylurea, although it was not as potent as retinyl acetate in this regard. However, the lesser toxicity of 4-hydroxyphenylretinamide makes it a superior agent for prevention of breast cancer. High-pressure liquid chromatographic analyses of liver and breast extracts from rats treated for 6 months with retinoids show the pharmacokinetic basis for the superiority of 4-hydroxyphenylretinamide; this retinoid and its metabolites were found in high concentrations in breast tissue, without any measurable accumulation in the liver or evident liver toxicity. In contrast, chronic feeding of retinyl acetate caused marked deposition of retinyl esters in the liver and severe hepatotoxicity. Whole mounts of rat mammary glands, made after chronic feeding of 4-hydroxyphenylretinamide, showed that it had a marked antiproliferative effect on mammary epithelium.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 421218

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

Review 1.  Novel agents for chemoprevention, screening methods, and sampling issues.

Authors:  Mary Jo Fackler; Ella Evron; Seema A Khan; Saraswati Sukumar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

2.  Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids.

Authors:  Q Wu; M I Dawson; Y Zheng; P D Hobbs; A Agadir; L Jong; Y Li; R Liu; B Lin; X K Zhang
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

Review 3.  Role of retinoid receptors in the prevention and treatment of breast cancer.

Authors:  L M Yang; C Tin-U; K Wu; P Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

4.  Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs.

Authors:  Serena M Mershon; Allyson L Anding; Jason S Chapman; Margaret Clagett-Dame; Laura A Stonerock; Robert W Curley
Journal:  Bioorg Med Chem Lett       Date:  2006-10-25       Impact factor: 2.823

5.  Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  Ruta D Rao; Melody A Cobleigh; Robert Gray; Mark L Graham; Larry Norton; Silvana Martino; George Thomas Budd; James N Ingle; William C Wood
Journal:  Med Oncol       Date:  2010-09-28       Impact factor: 3.064

Review 6.  Chemoprevention of breast cancer with fenretinide.

Authors:  R Torrisi; A Decensi; F Formelli; T Camerini; G De Palo
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide.

Authors:  Richard A Graves; Grace A Ledet; Elena Y Glotser; Demaurian M Mitchner; Levon A Bostanian; Tarun K Mandal
Journal:  Eur J Pharm Sci       Date:  2015-04-28       Impact factor: 4.384

Review 8.  Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment.

Authors:  Roisin M Connolly; Nguyen K Nguyen; Saraswati Sukumar
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

9.  Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1.

Authors:  Iván P Uray; Qiang Shen; Hye-Sook Seo; HeeTae Kim; William W Lamph; Reid P Bissonnette; Powel H Brown
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

10.  Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer.

Authors:  Huanxian Chen; Linmin Chen; Liang Wang; Xinhua Zhou; Judy Yuet-Wa Chan; Jingjing Li; Guozhen Cui; Simon Ming-Yuen Lee
Journal:  Cancer Biol Ther       Date:  2016-09-15       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.